{"id":"NCT01059539","sponsor":"Forest Laboratories","briefTitle":"Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder","officialTitle":"A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02-28","primaryCompletion":"2012-02-29","completion":"2012-02-29","firstPosted":"2010-02-01","resultsPosted":"2019-06-13","lastUpdate":"2019-06-13"},"enrollment":403,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"Cariprazine","otherNames":["RGH-188"]}],"arms":[{"label":"Cariprazine 3-12 mg/day for 16 weeks","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.","primaryOutcome":{"measure":"Change From Baseline in the YMRS Total Score at Week 16","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Cariprazine 3-12 mg/Day for 16 Weeks","deltaMin":-15.2,"sd":9.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":35,"countries":["United States","Hungary","Poland","Spain"]},"refs":{"pmids":["28843918"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":402},"commonTop":["Akathisia","Headache","Constipation","Nausea","Dyspepsia"]}}